Approval · Notice of Compliance 28364 · 2022
APTIVUS: Notice of Compliance 28364
Issued June 10, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28364
- Date
- June 10, 2022
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Migration of the Product Monograph (PM) to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APTIVUS | Not yet assigned | — |
Medicinal ingredients
- TIPRANAVIR 250 MG per CAP